AgomAb Therapeutics NV American Depositary Shares (AGMB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
AgomAb Therapeutics NV American Depositary Shares stock (AGMB) is currently trading at $11.64. Analyst consensus price target for AGMB is $32.00. WallStSmart rates AGMB as Sell.
- AGMB PE ratio analysis and historical PE chart
- AGMB PS ratio (Price-to-Sales) history and trend
- AGMB intrinsic value — DCF, Graham Number, EPV models
- AGMB stock price prediction 2025 2026 2027 2028 2029 2030
- AGMB fair value vs current price
- AGMB insider transactions and insider buying
- Is AGMB undervalued or overvalued?
- AgomAb Therapeutics NV American Depositary Shares financial analysis — revenue, earnings, cash flow
- AGMB Piotroski F-Score and Altman Z-Score
- AGMB analyst price target and Smart Rating
AgomAb Therapeutics NV American Depositary Shares
📊 No data available
Try selecting a different time range
Smart Analysis
AgomAb Therapeutics NV American Depositary Shares (AGMB) · 3 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around institutional own.. Significant fundamental concerns warrant caution or avoidance.
AgomAb Therapeutics NV American Depositary Shares (AGMB) Key Strengths (0)
Supporting Valuation Data
AgomAb Therapeutics NV American Depositary Shares (AGMB) Areas to Watch (3)
Very low institutional interest at 12.19%
Premium pricing at 3.6x book value
Small-cap company with higher risk but more growth potential
AgomAb Therapeutics NV American Depositary Shares (AGMB) Detailed Analysis Report
Overall Assessment
This company scores 10/100 in our Smart Analysis, earning a F grade. Out of 3 metrics analyzed, 0 register as strengths (avg 0/10) while 3 fall into concern territory (avg 3.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Institutional Own., Price/Book, Market Cap. Some valuation metrics including Price/Book (3.59) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Institutional Own. improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Institutional Own. and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AGMB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
Insider Transactions
Loading insider activity...
About AgomAb Therapeutics NV American Depositary Shares(AGMB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company is headquartered in Antwerp, Belgium.